Browsing Tag
LifeSci Capital
3 posts
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
QNCX: What does the reverse merger hunt at Quince Therapeutics mean for shareholders after the NEAT trial collapse?
Quince Therapeutics (Nasdaq: QNCX) has no pipeline and a September Nasdaq deadline. Here's what the reverse merger hunt actually means for retail investors watching this stock.